CHICAGO, Feb. 9, 2022 /PRNewswire/ -- According to the new market research report "Point of Care Molecular Diagnostics Market by Product (Assays, Kits, Analyzers, Service), Application (Respiratory Diseases, HAIs, STDs, Cancer, Hepatitis), Technology (RT-PCR, INAAT), End User (Physician Office, Hospitals, ICUs) - Global Forecast to 2026", published by MarketsandMarkets, the global Point-of-Care Molecular Diagnostics Market size is projected to reach USD 4.1 billion by 2026 from an estimated USD 2.8 billion in 2021, at an 8.2% CAGR.
Browse in-depth TOC on "Point of Care Molecular Diagnostics Market"
200 - Tables
44 - Figures
233 - Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=143524127
The increasing prevalence of infectious diseases and cancer, rising focus on decentralized diagnostics, increasing R&D funding, increasing awareness on the early detection of infectious diseases, and the increasing use of POC diagnostic tests drives growth in the point-of-care molecular diagnostics market. Emerging economies in Asia Pacific region are providing lucrative opportunities for the players operating in the point-of-care molecular diagnostics market.
The assays & kits segment accounted for the largest share of the point-of-care molecular diagnostics market, by product & service segment, in 2020
Based on products & service, the point-of-care molecular diagnostics market is segmented into assays & kits, instruments & analyzers, and software & services. In 2020, the assays & kits segment accounted for the largest share of this market. This is due to the frequent purchase of these products which drives the market growth of this segment.
RT-PCR segment accounted for the largest share during the forecast period
Based on technologies, the point-of-care molecular diagnostics market is segmented into RT-PCR, INAAT, and other technologies. In 2020, the RT-PCR segment accounted for the largest share of this market. Factors such as the growing use of RT-PCR in proteomics, genomics, and COVID-19 testing as well as the access to portable, easy-to-use devices are the major factors driving the growth of this market segment.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=143524127
The respiratory diseases segment accounted for the largest share of the point-of-care molecular diagnostics market, by application segment, in 2020
Based on application, the molecular diagnostics market is segmented into respiratory diseases, sexually transmitted diseases, hospital-acquired infections, cancer, hepatitis, gastrointestinal disorders, and other applications. In 2020, the respiratory diseases segment accounted for the largest share of this market. The increasing prevalence of infectious diseases and the outbreak of COVID-19 are major factors driving the growth of this market segment.
The physicians' offices segment accounted for the largest share of the point-of-care molecular diagnostics market, by end user segment, in 2020
Based on end users, the market is segmented into physicians' offices, hospitals & ICUs, research institutes, and other end users. In 2020, physicians' offices accounted for the largest share of this market. The large share of this market can be attributed to factors such as the increasing prevalence of infectious diseases, growing awareness about CLIA waiver tests, and rising technological advancements.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=143524127
North America is the largest regional market for point-of-care molecular diagnostics market
The point-of-care molecular diagnostics market is segmented into four regions, namely, North America, Europe, Asia Pacific and the Rest of the World. In 2020, North America accounted for the largest share of the point-of-care molecular diagnostics market. The large share of this region can be attributed to highly developed healthcare system in the US and Canada and the easy accessibility to technologically advanced instruments.
The major players operating in this market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Danaher Corporation (US), Quidel Corporation (US), QIAGEN N.V. (Netherlands), Co-Diagnostics, Inc. (US), Biocartis NV (Belgium), Meridian Bioscience, Inc. (US), Thermo Fisher Scientific, Inc. (US), Lucira Health, Inc. (US), Cue Health (US), OpGen, Inc. (US), Binx Health, Inc. (US), Molbio Diagnostics Pct. Ltd. (India), Genomadix (Canada), Visby Medical, Inc. (US), QuikPath PTE Ltd. (Singapore), MD-Bio (US), QuantuMDx Group Ltd. (UK), Aidian Oy (Finland), and GeneSTAT Molecular Diagnostics, LLC (US).
Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
Browse Related Reports:
ASEAN and North Asian Point of Care/Rapid Diagnostics Market by Product (Glucose Monitoring, COVID, HIV, STDs, HAIs, Influenza, Tropical & Respiratory diseases), Technique (Rapid test, Molecular diagnostics), User (Hospital, Home Care) - Forecast to 2026
https://www.marketsandmarkets.com/Market-Reports/asean-north-asian-point-care-rapid-diagnostics-market-219733165.html
Molecular Diagnostics Market by Product & Service (Reagents, Kits, PoC & Tabletop Instruments), Application (COVID-19, Hepatitis, HAI, HIV, Oncology, Genetic Tests), Technology (PCR, NGS, ISH), End User (Hospitals, Diagnostic Labs)-Global Forecast to 2026
https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html
About MarketsandMarkets
MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/point-of-care-molecular-diagnostic-market.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/point-of-care-molecular-diagnostic.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
